Delaware
(State
or other jurisdiction of incorporation)
|
1-08323
(Commission
File Number)
|
06-1059331
(IRS
Employer
Identification
No.)
|
[
]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
[
]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
[
]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
[
]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
1.
|
increased
medical costs that are higher than anticipated in establishing premium
rates in the Company’s health care operations, including increased use and
costs of medical services;
|
2.
|
increased
medical, administrative, technology or other costs resulting from new
legislative and regulatory requirements imposed on the Company’s employee
benefits businesses;
|
3.
|
challenges
and risks associated with implementing operational improvement initiatives
and strategic actions in the ongoing business operations, including those
related to: (i) offering products that meet emerging market needs, (ii)
strengthening underwriting and pricing effectiveness, (iii) strengthening
medical cost and medical membership results, (iv) delivering quality
member and provider service using effective technology solutions, (v)
lowering administrative costs, and (vi) transitioning to an integrated
operating company model, including operating efficiencies related to the
transition;
|
4.
|
risks
associated with pending and potential state and federal class action
lawsuits, disputes regarding reinsurance arrangements, other litigation
and regulatory actions challenging the Company’s businesses, government
investigations and proceedings, and tax audits;
|
5.
|
heightened
competition, particularly price competition, which could reduce product
margins and constrain growth in the Company’s businesses, primarily
the health care
business;
|
6.
|
risks
associated with the Company’s mail order pharmacy business which, among
other things, includes any potential operational deficiencies or service
issues as well as loss or suspension of state pharmacy licenses;
|
7.
|
significant
changes in interest rates for a sustained period of
time;
|
8.
|
downgrades
in the financial strength ratings of the Company’s insurance subsidiaries,
which could, among other things, adversely affect new sales and retention
of current business;
|
9.
|
limitations
on the ability of the Company’s insurance subsidiaries to dividend capital
to the parent company as a result of downgrades in the subsidiaries’
financial strength ratings, changes in statutory reserve or capital
requirements or other financial constraints;
|
10.
|
inability
of the program adopted by the Company to substantially reduce equity
market risks for
|
reinsurance
contracts that guarantee minimum death benefits under certain variable
annuities (including possible market difficulties in entering into
appropriate futures contracts and in matching such contracts to the
underlying equity risk);
|
|
11.
|
adjustments
to the reserve assumptions (including lapse, partial surrender, mortality,
interest rates and volatility) used in estimating the Company’s
liabilities for reinsurance contracts covering guaranteed minimum death
benefits under certain variable annuities;
|
12.
|
adjustments
to the assumptions (including annuity election rates and amounts
collectible from reinsurers) used in estimating the Company’s assets and
liabilities for guaranteed minimum income benefits under certain variable
annuities;
|
13.
|
significant
stock market declines, which could, among other things, result in
increased expenses for guaranteed minimum income benefit contracts,
guaranteed minimum death benefit contracts and pension expenses for the
Company’s pension plan in future periods as well as the recognition of
additional pension obligations;
|
14.
|
unfavorable
claims experience related to workers’ compensation and personal accident
exposures of the run-off reinsurance business, including losses
attributable to the inability to recover claims from
retrocessionaires;
|
15.
|
significant
deterioration in economic conditions and significant market volatility,
which could have an adverse effect on the Company’s
operations, investments, liquidity and access to capital
markets;
|
16.
|
significant
deterioration in economic conditions and significant market volatility,
which could have an adverse effect on the businesses of our customers
(including the amount and type of healthcare services provided to their
workforce and our customers' ability to pay receivables) and our vendors
(including their ability to provide services);
|
17.
|
changes
in public policy and in the political environment, which could affect
state and federal law, including legislative and regulatory proposals
related to health care issues, which could increase cost and affect the
market for the Company’s health care products and services; and amendments
to income tax laws, which could affect the taxation of employer provided
benefits, and pension legislation, which could increase pension
cost;
|
18.
|
potential
public health epidemics and bio-terrorist activity, which could, among
other things, cause the Company’s covered medical and disability expenses,
pharmacy costs and mortality experience to rise significantly, and cause
operational disruption, depending on the severity of the event and number
of individuals affected;
|
19.
|
risks
associated with security or interruption of information systems, which
could, among other things, cause operational
disruption;
|
20.
|
challenges
and risks associated with the successful management of the Company’s
outsourcing projects or key vendors, including the agreement with IBM for
provision of technology infrastructure and related
services;
|
21.
|
the
ability to successfully integrate and operate the businesses acquired from
Great-West by, among other things, renewing insurance and administrative
services contracts on competitive terms, retaining and growing membership,
realizing revenue, expense and other synergies, successfully leveraging
the information technology platform of the acquired businesses, and
retaining key personnel; and
|
22.
|
the
ability of the Company to execute its growth plans by
successfully managing Great-West Healthcare’s outsourcing projects and
leveraging the Company's capabilities and those of the business acquired
from Great-West to further enhance the combined organization’s network
access position, underwriting effectiveness, delivery of quality member
and provider service, and increased penetration of its membership base
with differentiated product
offerings.
|
CIGNA
CORPORATION
|
|
Date:
May 26, 2009
|
By:
/s/ Annmarie T.
Hagan
Annmarie T. Hagan
Vice
President, Chief Accounting Officer
and Corporate Controller |